Tag Archives: Christopher Marai

Syndax Pharmaceuticals (SNDX) Gets a Buy Rating from Nomura

In a report issued on May 22, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), with a price target of $31.00. The company’s shares closed last Friday at $16.00. According to TipRanks.com, Marai

Galapagos (GLPG) Receives a Buy from Nomura

In a report released today, Christopher Marai from Nomura maintained a Buy rating on Galapagos (GLPG – Research Report), with a price target of $290.00. The company’s shares closed last Thursday at $203.08. According to TipRanks.com, Marai is a 4-star

Nomura Thinks Solid Biosciences’ Stock is Going to Recover

In a report issued on May 18, Christopher Marai from Nomura maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target of $6.00. The company’s shares closed last Thursday at $3.01, close to its 52-week

Nomura Remains a Buy on Sarepta Therapeutics (SRPT)

Nomura analyst Christopher Marai maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on May 15 and set a price target of $230.00. The company’s shares closed last Friday at $141.25. According to TipRanks.com, Marai is a 4-star

CytomX Therapeutics (CTMX) Gets a Buy Rating from Nomura

In a report issued on May 14, Christopher Marai from Nomura maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $9.01. According to TipRanks.com, Marai

Nomura Reaffirms Their Buy Rating on MacroGenics (MGNX)

In a report issued on May 14, Christopher Marai from Nomura maintained a Buy rating on MacroGenics (MGNX – Research Report), with a price target of $50.00. The company’s shares closed last Friday at $25.80, close to its 52-week high